Loading...
By Amy Orciari Herman
Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM
Increases in televised direct-to-consumer testosterone ads were associated with increases in serum testosterone testing and treatment initiation over a 4-year period, a JAMA study finds.
Using television ratings and records from a U.S. health claims database, researchers examined testosterone advertising, testing, and treatment from 2009 to 2013. Over 17 million men were included; 6% had new serum testosterone tests and 2% began testosterone therapy during the study period. Average household testosterone ad exposure ranged from 0 ads in some months to 14 in December 2012.
Overall, each ad exposure was associated with 14 new testosterone tests, 5 new treatments, and 2 new treatments without diagnostic testing per 1 million men exposed.
An editorialist discusses safety concerns surrounding testosterone therapy, uncertain benefits, and the potential for overdiagnosis of androgen deficiency. He concludes that television advertising, "while a potentially powerful tool in motivating patient behavior and perhaps even physician prescribing, does not necessarily serve to improve the health of patients or the public."
Comment
LINK(S):
JAMA article (Free abstract)
JAMA editorial (Subscription required)
Background: Recent NEJM Journal Watch General Medicine coverage of testosterone therapy in older men (Your NEJM Journal Watch subscription required)